University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 3C-19-5


Relapsed/Refractory Microsatellite-stable (MSS) Colorectal Cancer (CRC) Immunotherapy-naïve Subjects Treated with Tilsotolimod in Combination with Nivolumab and Ipilimumab (Cohort 3) Main Study:Study of Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Cristina De Leon, Coordinator, Chi Nguyen, Coordinator, Maria Sharma, Coordinator, Leila Andres, Coordinator, Fahim Raian, D.M., Edwin Smura, Coordinator, Charlean Ketchens, Coordinator, Jiayi Jiang, D.M., Xiomara Menendez, Coordinator, Noureddine Miloud, D.M., Yanli Wang, D.M., Rabia Rehman, Coordinator, Atessa Kiani, Coordinator, Diana Oganyesyan, Coordinator, Janelle Luevano, Coordinator, Lauren Wagner, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.